- Net sales of Arzerra for the third quarter of 2010 were approximately DKK 78
million, with an expected royalty payment to Genmab of approximately DKK 15.6
million.
Copenhagen, Denmark; October 21, 2010 - Genmab A/S (OMX: GEN) announced today
that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010
were approximately DKK 78 million (approximately USD 14 million). Arzerra third
quarter net sales in the U.S. and the rest of the world were approximately DKK
69.3 million (approximately USD 12.7 million) and approximately DKK 8.7 million
(approximately USD 1.6 million) respectively. Under the terms of the
collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty
payment of approximately DKK 15.6 million (approximately USD 2.9 million).
Arzerra was granted accelerated approval by the FDA in October 2009, for the
treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that
is refractory to fludarabine and alemtuzumab. Arzerra was launched by GSK in
mid-November 2009. In April 2010, a conditional marketing authorization for the
treatment of CLL in patients who are refractory to fludarabine and alemtuzumab
was granted by the EU Commission.
The conversion to USD has been made using the Danish Central Bank closing spot
rate on September 30, 2010 of USD 1.00 = DKK 5.4601.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30, M: +45 25 27 47 13, E: h.husted@genmab.com
This Stock Exchange Release contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our products,
our inability to manage growth, the competitive environment in relation to our
business area and markets, our inability to attract and retain suitably
qualified personnel, the unenforceability or lack of protection of our patents
and proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and other
factors. For a further discussion of these risks, please refer to the section
“Risk Management” in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-TF(TM);
HuMax-Her2(TM); HuMax-Wnt(TM); HuMax-cMet(TM) and UniBody(R) are all trademarks
of Genmab A/S. Arzerra(R) is a trademark of GlaxoSmithKline.
Stock Exchange Release no. 41
###
